This result is especially important in the light of current European AIDS Clinical Society (EACS) guidelines that recommend the introduction of cART immediately after the confirmation of HIV-seropositive status, regardless of current immunological parameters (Ryom et al., 2016), contrary to the prior EACS guidelines that recommended commencing cART when CD4+ T cell counts were only below 350/μL (Clumeck et al., 2008). The gene discussed is CD4; the disease is AIDS.